Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation among Asian Chronic Hepatitis B Patients: an Important Addition

Abstract

We appreciate the comments from Wang et al and their efforts to explore the value of hepatitis B surface antigen (HBsAg) at the end of treatment (EOT) in nucleos(t)ide analogues (NAs) cessation. Although we didn't include the article¹ for unavailable clinical relapse data in the setting of different HBsAg levels at EOT, a cumulative incidence of 9.3%¹ for clinical relapse in chronic hepatitis B (CHB) patients with HBsAg < 100 IU/mL at EOT should be a strong support for conclusions in our review.²

This article is protected by copyright. All rights reserved.

http://bit.ly/2TrK4ac